Inhibrx Inc INBX

NAS: INBX | ISIN: US45720L1070   1/05/2025
12,32 USD (-0,08%)
(-0,08%)   1/05/2025

1 april 2025 · Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President · Persbericht

17 maart 2025 · Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results · Persbericht

14 augustus 2024 · Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights · Persbericht

24 mei 2024 · Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi · Persbericht

11 mei 2024 · Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off · Persbericht

8 mei 2024 · Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger · Persbericht

27 maart 2024 · TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX · Persbericht

12 maart 2024 · INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN · Persbericht

28 februari 2024 · Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results · Persbericht

23 januari 2024 · Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B · Persbericht

9 november 2023 · Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

2 november 2023 · Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma · Persbericht

18 oktober 2023 · Inhibrx Announces Participation in Upcoming Scientific Conferences · Persbericht

19 september 2023 · Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada · Persbericht

29 augustus 2023 · Inhibrx Announces $200 Million Private Placement Financing · Persbericht

7 augustus 2023 · Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

30 mei 2023 · Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency · Persbericht

8 mei 2023 · Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights · Persbericht

26 april 2023 · Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials · Persbericht

6 maart 2023 · Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results · Persbericht

Mijn selecties